Akihiro Miura

Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito et al. · Cancer Research · 2020 · 184 citations · Full text

Induction and expansion of human PRRX1+ limb-bud-like mesenchymal cells from pluripotent stem cells

Daisuke Yamada, Masahiro Nakamura, Tomoka Takao et al. · Nature Biomedical Engineering · 2021 · 52 citations · Full text

Regenerative Medicine, Induced Pluripotent Stem Cell, Developmental Biology +8

YES1 activation induces acquired resistance to neratinib in <i>HER2</i>‐amplified breast and lung cancers

Tatsuaki Takeda, Hiromasa Yamamoto, Ken Suzawa et al. · Cancer Science · 2019 · 23 citations · Full text

Oncogenic potential of human pluripotent stem cell‐derived lung organoids with <scp>HER2</scp> overexpression

Akihiro Miura, Daisuke Yamada, Masahiro Nakamura et al. · International Journal of Cancer · 2021 · 23 citations · Full text

Human Pluripotent Stem, Lung Adenocarcinoma, Stem Cell Biology +20

TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways

Akihiro Miura, Hiroshi Sootome, Naoya Fujita et al. · Investigational New Drugs · 2021 · 21 citations

Tumor Biology, Trk Inhibitor, Medicine +10